Related Experiment Videos
Topical alpha-interferon in recurrent conjunctival papilloma
R J W de Keizer1, D de Wolff-Rouendaal
1Department of Ophthalmology, Leiden University Medical Centre, Leiden, the Netherlands. r.j.w.de_keizer@lumc.nl
Acta Ophthalmologica Scandinavica
|May 20, 2003
Summary
Topical alpha-interferon (alpha-IF) effectively treated recurrent conjunctival papillomas in two cases. This adjuvant therapy led to regression and disappearance of papillomas, with no recurrences observed during long-term follow-up.
Area of Science:
- Ophthalmology
- Virology
- Oncology
Background:
- Recurrent conjunctival papillomas, often caused by human papillomavirus (HPV), pose a treatment challenge.
- Traditional treatments like excision and cryotherapy can lead to recurrence, necessitating alternative therapeutic strategies.
Observation:
- Two patients with recurrent conjunctival papillomas, including one with associated in situ carcinoma, were treated with systemic and topical alpha-interferon (alpha-IF).
- One patient received systemic alpha-IF followed by topical alpha-IF, while the other was treated solely with topical alpha-IF.
- Follow-up periods were 84 and 91 months, respectively.
Findings:
- Both patients experienced regression and disappearance of conjunctival papillomas.
- Topical alpha-IF demonstrated efficacy as an adjuvant therapy, preventing recurrence during extended follow-up.
- A potential side effect of superficial keratitis was noted with topical alpha-IF use.
- HPV types 6 and 33 were identified in the respective cases.
Implications:
- Topical alpha-interferon shows promise as an effective adjuvant treatment for recurrent conjunctival papillomas.
- This approach may offer a valuable alternative for managing challenging papilloma cases, potentially reducing recurrence rates.
- Further research into the optimal use and long-term safety of topical alpha-IF in ophthalmology is warranted.